[¹⁴C]Prexasertib + Prexasertib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer
Trial Timeline
Sep 22, 2016 → Jul 27, 2017
NCT ID
NCT02778126About [¹⁴C]Prexasertib + Prexasertib
[¹⁴C]Prexasertib + Prexasertib is a phase 1 stage product being developed by Eli Lilly for Advanced Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02778126. Target conditions include Advanced Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02778126 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Cancer